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Abstract 
Aims. The aim of this study was to evaluate the clinical and echocardiographic results and the predictors of 
outcomes in patients undergoing valve sparing operation (VSO) at two aortic centers. In addition, we sought 
to evaluate the potential effect of recreation of the sinuses of Valsalva (SV) on the outcome of valve sparing 
procedures.  
Methods. During a 14-year period 328 patients underwent aortic valve sparing root replacement at two 
Institutions.  Clinical and echo evaluation was performed 6 months after surgery and every year thereafter 
or in case of clinical symptoms. Propensity weighting and propensity-weighted risk competing analysis 
were used.  
Results. No operative mortality was reported; the most common complication was revision for bleeding, 
occurring in 15 patients (4.6%). At a mean follow-up of 30.0±33.9 months, 2 patients died (0.6%). 
Recurrent aortic insufficiency (AI) >2+ was found in 11 patients (3.3%); 5 (1.5%) underwent reoperation. 
Recreation of the SV did not affect clinical outcome and aortic valve status. Need for aortic valve repair 
was the only independent predictor of recurrent AI, whereas a bicuspid aortic valve was a protective factor.  
Conclusions. Re-creation of the SV does not affect short-term outcomes following VSO. 
Keywords: Valve sparing aortic surgery; Valsalva sinuses; David procedure. 
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Preservation of the patient’s native aortic valve offers substantial advantages over aortic valve replacement, 
avoiding potential prostheses-related complications and the need for long-term anticoagulation1. 
Nevertheless, aortic valve sparing operation (VSO) may be technically challenging: significant experience 
is required not only to perform the procedure but also to select the appropriate patients and valve pathology 
in order to obtain favorable results.  
The importance of the recreation of the sinuses of Valsalva (SV) during aortic VSO remains a matter of 
controversy. Despite solid experimental and in vivo evidence of the physiologic importance of the SV for 
aortic valve function2,3, there is limited data comparing the outcome of patients undergoing VSO with and 
without SV reconstruction. 
We present the clinical and echocardiographic results of 328 patients undergoing aortic VSO at two centers 
and compare the outcomes of patients with and without neo-SV.  
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Methods 
The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a 
priori approval by both the institutions’ human research committee. The need for individual patient consent 
was waived. 
Review of prospectively collected data from the aortic surgery databases of the Weill Cornell Medical 
College Department of Cardiothoracic Surgery in New York and the Department of Cardiac Surgery of the 
European Hospital in Rome was conducted to identify all consecutive patients who underwent VSO from 
September 2002 to November 2015. 
Primary end-points were operative mortality, all cause death at follow-up, reoperation on the aortic valve 
and echocardiographic evidence of recurrent aortic insufficiency (AI) >2+ at follow-up. Secondary 
endpoints were the incidence of major postoperative complications (myocardial infarction, cerebro-
vascular accident with permanent deficit, respiratory failure leading to tracheostomy, acute renal 
insufficiency requiring dialysis, deep sternal wound infection) and a composite index of major 
postoperative adverse events (MAE: operative death and major postoperative complications).  
Surgical treatment was indicated by valvular and aortic pathologic criteria according to the established best-
practice, ESC/EACTS4 and AHA/ACC5 guidelines. Details of the surgical techniques used in the two 
centers have been previously published6,7.  
All operations were performed using median sternotomy, central cannulation, moderate hypothermic 
cardiopulmonary bypass, aortic cross-clamping and myocardial protection with cold antegrade blood 
cardioplegia. In both centers the classical David 1 technique was used8. At Weill Cornell Medical College, 
a straight Dacron tube without SV was always employed (Macquet Corp, Fairfield, NJ, USA), whereas at 
the European Hospital a graft with neo-SV was used for all cases (Vascutek® Gelweave Valsalva™ Grafts, 
Terumo, Inchinnan, Scotland, United Kingdom). 
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The databases of both Institutions are constantly updated and maintained by a team of clinical information 
analysts; data collection is validated regularly by means of external and internal control. Pre- and 
perioperative variables are entered prospectively during in-hospital stay. Postoperatively, follow-up clinical 
and transthoracic echo evaluation is performed at 6 months after surgery and every year thereafter or in 
case of clinical symptoms suggestive of aortic disease. Aortic regurgitation is assessed by color-flow 
Doppler techniques in the standard transthoracic views and graded according to the current guidelines9. In 




Continuous variables were summarized statistically with standard deviations in addition to means and with 
counts in addition to percentages for categorical variables. The chi squared test was used to test unadjusted 
association between treatment variable and outcomes.  
For intergroup comparison, crude incidences of outcomes were reported in the whole sample according to 
the type of graft used (graft with neo-SV versus graft without neo-SV). In order to assess the effect of graft 
selection on the incidence of postoperative recurrent aortic regurgitation and need for reintervention we 
conducted a propensity score based analysis on patients who underwent surgery for chronic aneurysm only. 
Inverse probability of treatment weighting for modelling causal effects was used for treatment effects 
comparison. A generalised boosted model was implemented to estimate logistic propensity scores (PS) 
adjusting for pre-treatment covariates including the morphology of the aortic valve and the preoperative 
degree of AI, and the propensity score was assumed as the probability that an individual of the Valsalva 
group receives the straight tube graft (twang R package).The average treatment effect on the treated was 
used to answer the question of how, on average, the outcome of interest would change if everyone assigned 
to a particular treatment would have received another treatment. The absolute standardised mean difference 
was used as a balance metric to summarize the difference between two univariate distributions of a single 
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pre-treatment variable. A value ≥0.20 (20%) was considered as an indicator of imbalance. Effective sample 
size was calculated to account for the potential loss in precision from weighting10. We then estimated the 
treatment effect estimates with a weighted competing risk analysis regression model that contained only a 
treatment indicator11.  R version 3.1.2 (2014-10-31), twang and cmprsk packages were used for all statistical 
analysis. 
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Results 
During the study period 328 patients underwent VSO at the two Institutions (227 at Weill Cornell Medical 
College and 101 at the European Hospital). The main pre- and intraoperative characteristics of these patients 
are summarized in Table 1. 
The majority of the patients were males in their fifth decade and in New York Heart Association (NYHA) 
class 1 or 2, and 20% of them had connective tissue disorders.  
No operative mortality was reported in both centers. The type and incidence of postoperative complications 
are summarized in Table 2. Re-exploration for bleeding was the most common postoperative adverse event 
(15 cases, 4.6%). Dialysis-requiring new onset renal insufficiency occurred in two cases (0.6%) and 
postoperative myocardial infarction in one case (0.3%). The overall incidence of MAE was 0.9%. At 
discharge, no patients had echocardiographic evidence of AI >1+.  
Mean follow-up duration for the overall population was 30.0±33.9 months (mean follow-up of patients 
receiving neo-SV versus those not receiving neo-SV: 54.5±42.1 versus 19.1±22.2 months, respectively). 
Completeness of follow-up was 100%. During this period, two patients died (overall mortality: 0.6%) 
(Figure 1) and 11 patients (5.6%) developed AI >2+ (Table 3, Figure 2B). Five of these patients (1.5% of 
the total) required reoperation on the aortic valve (Table 3, Figure 2A). All cases of reoperations were due 
to structural valve deterioration.  
No difference in operative outcome was found between the two unweighted groups (Tab 2 and 3). During 
follow-up 1 patient from each group died (p=.55). The Kaplan-Meier survival curves of the two unweighted 
groups are reported in Figure 1. There were three cases of reoperation in the neo-SV graft group and 2 in 
the group of patients receiving a graft without neo-SV (p=.86). Six patients in the neo-SV group and 5 in 
the group without neo-SV developed recurrent AI >2+ (p=.28). 
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A total of 97 patients receiving a neo-SV graft and 220 receiving a graft without neo-SV for chronic aortic 
aneurysm were included in a propensity based analysis. After PS weighting the two groups were 
comparable for all pre-treatment variables (Supplementary Table 1 and Supplementary Figure 1). 
PS-weighted risk competing analysis showed that the two groups presented similar short-term mortality 
and incidence of reoperation (Figure 3A). The neo-SV graft group and the group of patients receiving a 
graft without neo-SV also presented a comparable incidence of AI >2+ at follow-up (Figure 3B). By 
performing a full adjustment, we found that the need for aortic valve repair was the only independent 
predictor of follow-up AI >2+, whereas bicuspid aortic valve was a protective factor (p<.0001 for both).  
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Discussion 
The term “aortic VSO” was introduced in the early 1990s in order to define those procedures in which 
aortic valve cusps were preserved in patients with aortic root/ascending aorta aneurysm. Two different 
techniques were first described12: the “remodeling” technique (or “Yacoub” technique)13 which reduces the 
sinotubular junction diameter and creates three neo-SV with a scalloped Dacron tube graft sutured in the 
supravalvular position, and the “reimplantation” technique (or “David” technique)8, by which the aortic 
valve is resuspended into a straight prosthetic tube.  
Preservation of the patient’s native aortic valve in case of aortic root surgery offers substantial advantages 
over aortic valve replacement. Avoidance of the need for long-term anticoagulation and potential 
mechanical prostheses-related complication, as well as low durability and rapid degeneration in case of 
biological prostheses are strong arguments in favor of VSO over traditional surgery. Price et al. evaluated 
long-term outcomes of aortic root operations in 165 patients with Marfan syndrome who underwent a 
Bentall or VSO. While late survival, freedom from root reoperation, and freedom from endocarditis were 
similar in the two groups, VSO resulted in significantly fewer thromboembolic and hemorrhagic events 
(hazard ratio, 0.16; 95% confidence interval, 0.03-0.85; p= .03)14. In a prospective multicenter study, 
Coselli and colleagues compared 1-year results after aortic VSO or aortic valve replacement in 316 patients 
with Marfan syndrome15. Survival was similar between the 2 groups but AI >2+ at follow-up was present 
in 16 patients in the VSO group (7%) versus no patients in the valve replacement group (p= .02).   Long-
term outcomes following 4 different types of aortic root procedures combined with ascending aorta 
replacement for aneurysm in 957 patients were studied by Svensson et al16. At 10 years, patients in the VSO 
and allograft groups were more likely to show severe AI (24% and 19%, respectively; p= .2) when 
compared to those who received a biologic or a mechanical composite graft (2.7% and 0%, respectively). 
Patients who underwent composite graft replacement with a biologic valve had the worst survival (p< 
.0001), mainly attributable to differences in patients’ characteristics. VSO and allograft procedures had the 
lowest gradients and best ventricular remodeling as well as less risk of valve-related complications, such 
as bleeding, hemorrhage, and endocarditis.  
  10 
An important issue regarding VSO is whether concomitant aortic cusp repair may influence valve function 
over time. Consistent with previous findings from other groups17, we found that the need for aortic valve 
repair was an independent predictor of AI at follow-up. Although several factors may play a role in this 
context, we believe that secondary fibrotic retraction of the cusp margins after interventions may be critical 
in this regard. 
Our findings on the protective effect of bicuspid aortic valves, although counterintuitive at first, is probably 
explained by a selection bias. It is likely that the operating surgeons had an instinctively higher threshold 
for VSO in case of bicuspid valves and thus selected only the best valves for VSO. Our findings confirm 
that bicuspid valves may be safely spared during VSO, as reported by others18,19. However, a longer follow-
up period will be necessary to determine whether reimplantation of BAVs during VSO will result in less 
freedom from reoperation due to structural deterioration of the BAV. 
In case of VSO, the use of tube graft with neo-SV, mimicking the native structure and dynamics, should 
theoretically be able to affect valve durability since perturbations of the regular movements of opening and 
closure of the native aortic valve and alterations in flow dynamics may be avoided20. SV were also 
demonstrated to have a key role in optimizing the aortic haemodynamics during systole, minimizing energy 
losses2. In addition, Welter and colleagues using finite element computer-assisted stress analysis were able 
to show that the use of a standard tubular graft can be linked to higher stress to coronary sutures, while 
using a graft with preformed SV could relieve stress on the coronary anastomoses, potentially decreasing 
the incidence of postoperative complications such as bleeding and late pseudoaneurysm formation3. 
However, the clinical impact of these physiological considerations has not been well determined and, 
consequently, the importance of the recreation of the SV at the time of VSO remains a matter of controversy. 
Recently the Toronto group reported its 20-year experience with VSO21. The authors used a straight tube 
graft in 216 patients and a tube with neo-SV in 117. On univariate analysis recreation of the SV was 
associated with the development of moderate or severe AI during follow-up (HR 1.87, 95%CI 1.03-3.42, 
p=.04). However, this was not confirmed on multivariate analysis. Of note, no attempt to match the clinical 
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or valvular characteristics of patients of the two groups was performed. Our study revealed that short-term 
outcomes are independent from neo-SV re-creation. The clinical outcome, the incidence of recurrent AI 
>2+ and of reoperation on the aortic valve were in fact similar in the group with and without neo-VS (see 
Figures 1-3). It must also be noted that a trend toward better freedom from AI and reoperation in the Non 
Neo-SV series was evident in our series. Although this difference did not reach statistical significance, this 
observation requires further investigation in a larger sample size. 
Some limitations of our study should be acknowledged. Due to the extremely low rate of adverse events, it 
is not possible to exclude that small differences in favor of one of the other technique could have been 
undetected. Also, this study is limited to short-term data, a longer follow-up is needed. The fact that the 
two study Institutions exclusively adopted one of the two techniques and that the two groups of patients are 
from different countries may have also influenced the outcomes. Finally, although PSM analysis was 
performed, it cannot substitute for a randomized controlled study.  
In conclusion, the results of VSO are excellent. Recreation of the VS during aortic VSO does not affect 
clinical outcome and aortic valve status. Additional multi-institutional studies with long term follow-up 
will be necessary to confirm our findings.   
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No Neo-SV  
(n=227) 
p 
Age (mean, std. dev.) 49.9 ±13.9 52.8 ±12.8 48.6 ±14.2 .013 
Male 273 (83.2) 85 (84.2) 188 (82.8) .764 
Chronic pulmonary disease 3 (0.9) 2 (2.0) 1 (0.4) .176 
Diabetes 5 (1.5) 2 (2.0) 3 (1.3) .653 
Previous cardiac surgery 9 (2.7) 1 (1.0) 8 (3.5) .195 
Connective tissue disorder 63 (19.2) 15 (14.9) 48 (21.1) .182 
Aortic dissection     
Acute 11 (3.4) 4 (4.0) 7 (3.1) 
.378 
Chronic 4 (1.2) 0 (0.0) 4 (1.8) 
NYHA >2 24 (7.3) 7 (6.9) 17 (7.5) .858 
Ejection Fraction <0.45 15 (4.6) 1 (1.0) 14 (6.2) .038 
Renal Status     
Creatinine > 1.5 mg/dL 7 (2.1) 5 (5.2) 2 (0.9) .033 
.246 Hemodialysis 3 (0.9) 0 (0.0) 3 (1.3) 
Bicuspid Valve 64 (19.5) 14 (13.9) 50 (22.0) .085 
Aortic Insufficiency     
  17 
0-2+ 229 (69.8) 69 (68.3) 160 (70.5) 
.693 
>2+ 99 (30.2) 32 (31.7) 67 (29.5) 
Circulatory arrest  26 (7.9) 5 (5.0) 21 (9.3) .183 
Crossclamp time (min) 111.4 ±21.7 104.7 ±18.9 114.4 ±22.2 <.001 
Concomitant procedures 96 (29.3) 27 (26.7) 69 (30.4) .501 
Aortic Valve Repair 25 (7.6) 8 (7.9) 17 (7.5) .892 
Data presented as n (%), unless otherwise noted. Mean data is ± standard deviation 
NYHA, New York Heart Association; SV, sinuses of Valsalva.   
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Table 2. In hospital outcome in the unweighted sample. 




No Neo-SV  
(n=227) 
p 
Operative death 0 (0.0) 0 (0.0) 0 (0.0) NS 
Myocardial infarction 1 (0.3) 1 (1.0) 0 (0.0) .133 
New need for dialysis 2 (0.6) 0 (0.0) 2 (0.9) .344 
Gastrointestinal complications 3 (0.9) 0 (0.0) 3 (1.3) .246 
Revision for bleeding 15 (4.6) 6 (5.9) 9 (4.0) .429 
Data presented as n (%), unless otherwise noted 
*Defined as postop creatinine >2 mg/dl 
SV, sinuses of Valsalva. 
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No Neo-SV  
(n=227) 
p 
Follow-up death 2 (0.6) 1 (1.0) 1 (0.4) .555 
Aortic Insufficiency     
0-2+ 186 (94.4)* 86 (93.5)* 100 (95.2)* 
.930* 
>2+ 11 (5.6)* 6 (6.5)* 5 (4.8)* 
Reoperation on the aortic valve 5 (1.5) 3 (3.0) 2 (0.9) .154 
Data presented as n (%), unless otherwise noted. 
*Percentages and p value were calculated based on the total number of patients for whom the echo 
follow-up was available (n=197 in the overall population; n=92 in the Neo-SV group; n=105 in the No 
Neo-SV group) 
SV, sinuses of Valsalva. 
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Figure legend 1 
Figure 1. Kaplan-Meier survival curves of the overall sample and the two unweighted groups. 2 
Figures 2A and 2B. Cumulative incidence of reoperation on the aortic valve and cumulative incidence of 3 
postoperative aortic insufficiency >2+ at follow-up of the two unweighted groups. 4 
Figures 3A and 3B. Short-term mortality, incidence of reoperation and incidence of aortic insufficiency 5 
>2+ at follow-up of the two PS-weighted groups. 6 
 7 
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